Cibc World Markets Corp Buys 21,329 Shares of Becton, Dickinson and Company (NYSE:BDX)

Cibc World Markets Corp raised its stake in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 133.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 37,341 shares of the medical instruments supplier’s stock after purchasing an additional 21,329 shares during the period. Cibc World Markets Corp’s holdings in Becton, Dickinson and Company were worth $9,105,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of BDX. Mendel Money Management lifted its holdings in shares of Becton, Dickinson and Company by 3.0% during the 3rd quarter. Mendel Money Management now owns 1,536 shares of the medical instruments supplier’s stock worth $397,000 after acquiring an additional 45 shares during the last quarter. CWM LLC lifted its holdings in shares of Becton, Dickinson and Company by 0.7% during the 4th quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after acquiring an additional 46 shares during the last quarter. S.A. Mason LLC lifted its holdings in shares of Becton, Dickinson and Company by 3.5% during the 4th quarter. S.A. Mason LLC now owns 1,420 shares of the medical instruments supplier’s stock worth $346,000 after acquiring an additional 48 shares during the last quarter. Edge Capital Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 3.1% during the 4th quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock worth $384,000 after acquiring an additional 48 shares during the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. lifted its holdings in shares of Becton, Dickinson and Company by 1.3% during the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,951 shares of the medical instruments supplier’s stock worth $963,000 after acquiring an additional 49 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $240.15 on Friday. Becton, Dickinson and Company has a 1 year low of $224.00 and a 1 year high of $287.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The company’s 50-day moving average is $235.90 and its 200 day moving average is $237.94. The stock has a market capitalization of $69.41 billion, a P/E ratio of 52.90, a P/E/G ratio of 2.07 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.86 earnings per share. On average, sell-side analysts expect that Becton, Dickinson and Company will post 13.03 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.58%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insider Activity

In other news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Roland Goette sold 3,300 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total transaction of $781,209.00. Following the transaction, the executive vice president now owns 11,308 shares in the company, valued at approximately $2,676,942.84. The disclosure for this sale can be found here. Insiders have sold a total of 8,597 shares of company stock worth $2,028,786 over the last 90 days. 0.31% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective for the company. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Barclays boosted their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $280.17.

Check Out Our Latest Research Report on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.